Make Informed Investment Decisions with Affordable Access to Experts
Exploring the Market Potential of Jazz Pharma's JZP-110 for the treatment of Obstructive Sleep Apnea (OSA) and Narcolepsy and how it compares to XyremTicker(s): JAZZ, AVDL
Name: Dr Alberto Ramos - MD
Institution: University of Miami
- Associate Professor of Clinical Neurology and Co-Director of the Sleep Disorders program at the University of Miami, Miller School of Medicine.
- Treats hundreds of patients with OSA & 20 patients with narcolepsy and is Board certified in both Neurology and Sleep Medicine.
- Research focus is on sleep and cerebrovascular disease in population based studies. He has been involved in a number of NIH sponsored studies in this area an is currently working on the K12 research study at the Miller School of Medicine evaluating cerebral hemodynamics and impaired cerebral vasomotor reactivity in obstructive sleep apnea within the Hispanic Community.
Please describe your current practice. How many patients do you treat with OSA? With Narcolepsy?Added By: c_admin
Is Hetlioz mechanistically superior in treating non24 compared to regular melatonin?Added By: c_admin
How well tolerated is JZP-110? What % of patient population would not be prescribed the drug due to side effects?Added By: c_admin
Is there anything else on the horizon for OSA that you think is promising?Added By: c_admin
On a scale from 1-10, where would you put your level of excitement for JZP-110?Added By: c_admin
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.